Furthermore, anti-TNF originators were used more than their biosimilars, and nonbiologic therapies used in combination with biologic agents were an important feature in the treatment pathways of patients with IBD, although no clear pattern of use was evident in this study. The gene discussed is TNF; the disease is inflammatory bowel disease.